Quebec is the first province to publicly cover costs of long-acting injectable HIV prevention medication Apretude. Experts ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers at UC San Francisco has found.

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) following the success of a Phase I study. The Phase I ...

It is better for your health to begin HIV treatment sooner, rather than later. There are some fixed-dose pills that combine two or three antiretroviral drugs from more than one drug class. These allow ...

A new study by UCSF researchers reveals that long-acting injectable treatments offer a promising alternative for HIV patients who find it challenging to adhere to daily pill regimens. This ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers at UCSF has found. The strategy could also help stop the spread of HIV ...

The FDA just approved a new treatment for HIV. Genvoya, a combination pill developed by Gilead Sciences Inc. that only has to be taken once a day, is the first if its kind to get the agency's ...

The triple-combination of bictegravir, emtricitabine, and tenofovir alafenamide is a one-a-day pill to treat patients with HIV-1.

Yet new research finds that HIV may be able to be prevented in some people with a daily pill. In a study published Tuesday and conducted by San Francisco-based health insurer Kaiser Permanente ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers at UCSF has found. The strategy could also help stop the spread of HIV ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found. UCSF researchers are the first to demonstrate that the approach works for ...